B+
Bull case
20%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
DBVT
DBVCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.4
Score
AI commentary
The Q2/H1 update provides supportive operating and regulatory context, but the packet contains no recent-news feed, social coverage, post-print price reaction, or analyst revision data. Low coverage and the negative deterministic return prior support a tentative, monitoring-style stance rather than a strong bullish conclusion.
RankAlpha Sentiment Codex - 2026-08-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-02eventQ3 2026 optimized BLA submissionHigh impact
DBV plans to submit an optimized BLA for the VIASKIN Peanut Patch in children aged 4–7 during Q3 2026. Management said FDA discussions are constructive and no additional data were requested; remaining work concerns organization, mapping, and formatting of existing CMC and biostatistical data. [#SEC-8K-2026-07-16] [#EARNINGS-TRANSCRIPT-2026Q2]
2026-11-02catalystBinary regulatory and commercialization executionHigh impact
DBV is investing in commercial preparedness ahead of potential approval. Cash of $174.9 million was reported as of June 30, 2026, with funding projected into Q3 2027, but delays, unfavorable review outcomes, or higher launch costs could pressure the shares. [#PR-EARNINGS-2026-07-16]
2027-08-04catalystFDA review and potential approvalHigh impact
A successful BLA submission could initiate review and create a pathway toward potential U.S. commercialization, but approval remains uncertain and the timing is not confirmed.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology